Biotech Values

[pcrutch]

PFE/BMY ELIQUIS(apixaban) news wrap up with links to multiple articles

NEJM article - Apixaban versus Warfarin in Patients with Atrial Fibrillation - http://bit.ly/q49394

Forbes' Matthew Herper: Pfizer and Bristol Overtake Rivals In Multi-Billion Blood Thinner Market - http://onforb.es/rtunCn

Forbes' - Pfizer and Bristol's ARISTOTLE Study Finds the Golden Mean of Anticoagulation - http://onforb.es/pguVe0

Fierce Biotech - Pfizer, BMS unveil mega-blockbuster data on apixaban - http://bit.ly/q5pBaE

Bloomberg - Pfizer, Bristol-Myers Experimental Blood Thinner Reduced Deaths in Study - http://bloom.bg/phjmdN

"Results of this caliber may mean that while the drug lags behind two rivals in the race to win approval in the U.S., it could still take up to half of the market, Christopher Schott, a New York-based analyst for JPMorgan Chase & Co., wrote in a note to investors before the data was public. Schott said a “best- case scenario” may add $1 billion in peak annual sales to the $2.8 billion he estimated Eliquis will generate by 2017."

[ in my view, the data would seem to fall under best-case scenario. ]

Reuters - http://reut.rs/oxw1W0

WSJ: Boost for New Stroke-Prevention Drug - http://on.wsj.com/qZ0L6T